Sara Vandenwijngaert

Sara Vandenwijngaert is currently a Junior Partner and Investment Manager at Qbic Fund, a venture capital fund focusing on seed and early-stage investments. Sara also serves as a Board Member at Tanai Therapeutics, ABSCINT, and THERAtRAME. With previous experience as an Associate Director Project Management at Medpace, Sara has a strong background in clinical trials. Sara has also held roles at One Brave Idea and Harvard Medical School, where Sara was involved in research and program leadership. Sara holds a Ph.D. in Biomedical Sciences (Cardiovascular Medicine) from KU Leuven and has a Master's and Bachelor's degree in Biomedical Sciences from the same institution. Additionally, Sara completed the CORe program at Harvard Business School Online.